Access our review in Journal of Translational
Journal of Translational Science
A review of GOLPH2, an oncogenic protein
and novel therapeutic options for GOLPH2 driven tumors
Witterswil and Basel, Switzerland
Access our publication in Targeted Oncology via
European Antibody Congress 2019
Egotumab, a human antibody targeting GOLPH2 in colorectal cancer was presented at the European Antibody Congress 2019 in Basel, Switzerland.
3rd Annual Next Gen Immune-Oncology Congress 2019
Egotumab, a human antibody against colorectal cancer, was presented at the Poster Session on 15.03.2019 in London, UK.
European Antibody Congress 2018
Egotumab, a human antibody against colorectal cancer, was presented in a keynote lecture on Wednesday 31.10.2018 in Basel, Switzerland.
BaseLaunch selected CUREAB for phase I of its accelerator program in 2018
we strive to provide patients with novel next generation antibodies for better cancer therapies in tumours with a high medical need. Colorectal Cancer will be the beginning.